These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 20627663)

  • 1. The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.
    Semenova S; Markou A
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):731-46. PubMed ID: 20627663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats.
    Bruijnzeel AW; Ford J; Rogers JA; Scheick S; Ji Y; Bishnoi M; Alexander JC
    Pharmacol Biochem Behav; 2012 Mar; 101(1):62-8. PubMed ID: 22182462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clozapine treatment attenuated somatic and affective signs of nicotine and amphetamine withdrawal in subsets of rats exhibiting hyposensitivity to the initial effects of clozapine.
    Semenova S; Markou A
    Biol Psychiatry; 2003 Dec; 54(11):1249-64. PubMed ID: 14643093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats.
    Bruijnzeel AW; Bishnoi M; van Tuijl IA; Keijzers KF; Yavarovich KR; Pasek TM; Ford J; Alexander JC; Yamada H
    Psychopharmacology (Berl); 2010 Dec; 212(4):485-99. PubMed ID: 20697697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
    Harrison AA; Liem YT; Markou A
    Neuropsychopharmacology; 2001 Jul; 25(1):55-71. PubMed ID: 11377919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.
    Liechti ME; Markou A
    Eur J Pharmacol; 2007 Jan; 554(2-3):164-74. PubMed ID: 17113075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of 5-HT2A receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow.
    Frånberg O; Marcus MM; Svensson TH
    Synapse; 2012 Jul; 66(7):650-60. PubMed ID: 22362425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of serotonin (5-HT)2 receptor-targeting ligands on locomotor responses to nicotine-repeated treatment.
    Zaniewska M; McCreary AC; Wydra K; Filip M
    Synapse; 2010 Jul; 64(7):511-9. PubMed ID: 20196140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats.
    Skjei KL; Markou A
    Psychopharmacology (Berl); 2003 Jul; 168(3):280-92. PubMed ID: 12712232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal from chronic exposure to amphetamine, but not nicotine, leads to an immediate and enduring deficit in motivated behavior without affecting social interaction in rats.
    Der-Avakian A; Markou A
    Behav Pharmacol; 2010 Jul; 21(4):359-68. PubMed ID: 20571366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M100907, a selective 5-HT(2A) receptor antagonist, attenuates phencyclidine-induced Fos expression in discrete regions of rat brain.
    Habara T; Hamamura T; Miki M; Ohashi K; Kuroda S
    Eur J Pharmacol; 2001 Apr; 417(3):189-94. PubMed ID: 11334850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy.
    Knauer CS; Campbell JE; Galvan B; Bowman C; Osgood S; Buist S; Buchholz L; Henry B; Wong EH; Shahid M; Grimwood S
    Eur J Pharmacol; 2008 Sep; 591(1-3):136-41. PubMed ID: 18593577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models and treatments for addiction and depression co-morbidity.
    Paterson NE; Markou A
    Neurotox Res; 2007 Jan; 11(1):1-32. PubMed ID: 17449445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats.
    Rylkova D; Boissoneault J; Isaac S; Prado M; Shah HP; Bruijnzeel AW
    Neuropeptides; 2008 Jun; 42(3):215-27. PubMed ID: 18468678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission.
    Marcus MM; Wiker C; Frånberg O; Konradsson-Geuken A; Langlois X; Jardemark K; Svensson TH
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):891-903. PubMed ID: 19835668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The α₂-adrenergic antagonist idazoxan counteracts prepulse inhibition deficits caused by amphetamine or dizocilpine in rats.
    Larrauri JA; Levin ED
    Psychopharmacology (Berl); 2012 Jan; 219(1):99-108. PubMed ID: 21710169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats.
    Varty GB; Bakshi VP; Geyer MA
    Neuropsychopharmacology; 1999 Apr; 20(4):311-21. PubMed ID: 10088132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants.
    Uslaner JM; Smith SM; Huszar SL; Pachmerhiwala R; Hinchliffe RM; Vardigan JD; Hutson PH
    Psychopharmacology (Berl); 2009 Nov; 206(4):641-51. PubMed ID: 19707745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonizing serotonin 2A (5-HT
    Madden JT; Reyna NC; Pentkowski NS
    Drug Alcohol Depend; 2020 Oct; 215():108178. PubMed ID: 32739601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
    Bonaccorso S; Meltzer HY; Li Z; Dai J; Alboszta AR; Ichikawa J
    Neuropsychopharmacology; 2002 Sep; 27(3):430-41. PubMed ID: 12225700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.